{"analyses":[{"ciLowerLimit":"0.77","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.13","groupIds":["OG000","OG001"],"nonInferiorityComment":"No power calculation for secondary analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.46","paramType":"Hazard Ratio (HR)","paramValue":"0.93","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"91","upperLimit":"93","value":"92"},{"groupId":"OG001","lowerLimit":"91","upperLimit":"93","value":"92"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3789"},{"groupId":"OG001","value":"3787"}],"units":"Participants"}],"description":"Overall survival is defined as the time from randomization to the time of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral exemestane (25 mg) once daily for 5 years.\n\nexemestane: Given orally","id":"OG000","title":"Exemestane"},{"description":"Patients receive oral anastrozole (1 mg) once daily for 5 years.\n\nanastrozole: Given orally","id":"OG001","title":"Anastrozole"}],"paramType":"NUMBER","populationDescription":"Intend to treat","reportingStatus":"POSTED","timeFrame":"5 years","title":"Overall Survival: Percentage of Participants Alive at 5 Years","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}